{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:37:22Z","timestamp":1776382642802,"version":"3.51.2"},"reference-count":29,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Hepato Biliary Pancreat"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs is an innovative treatment for advanced somatostatin\u2010positive neuroendocrine tumors (NETs). PRRT cannot be performed in Japan because there is no approval or insurance cover so far.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We relied on foreign institutions to perform PRRT for Japanese patients with NETs. We retrospectively evaluated the safety and efficacy of PRRT. The inclusion criteria were pathologically confirmed well\u2010differentiated NET and visible tumor uptake on pre\u2010therapeutic somatostatin receptor scintigraphy. <jats:sup>177<\/jats:sup>Lu\u2010DOTA\u2010TOC was used as the standard treatment, and patients received three infusions every 8\u00a0weeks. Until the end of 2017, combination treatment with <jats:sup>90<\/jats:sup>Y and <jats:sup>177<\/jats:sup>Lu\u2010DOTA\u2010TOC was performed using the same protocol.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010five patients were evaluated, and the primary lesions were pancreas, rectum, small intestine, stomach, and other locations. The partial response rate was 42.9%. Progression\u2010free survival (PFS) was 12.8\u00a0months and overall survival was 42.8\u00a0months. There was no significant difference in PFS between front\u2010line and late\u2010line PRRT (11.0\u00a0months vs 28.0\u00a0months; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.383). Severe adverse events included lymphocytopenia (20.0%) and thrombocytopenia (5.7%). Myelodysplastic syndrome occurred in one case.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>PRRT was effective and safe for Japanese patients with advanced NETs. PRRT was equally effective as front\u2010line and late\u2010line treatment.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jhbp.1014","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T16:49:23Z","timestamp":1624726163000},"page":"727-739","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors"],"prefix":"10.1002","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9181-3722","authenticated-orcid":false,"given":"Noritoshi","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Oncology Yokohama City University Graduate School of Medicine Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damian","family":"Wild","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine University Hospital Basel Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Kaul","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine University Hospital Basel Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Shimamura","sequence":"additional","affiliation":[{"name":"Shimamura Clinic Kawasaki Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Yokohama City University Graduate School of Medicine Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuma","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Oncology Yokohama City University Graduate School of Medicine Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Okubo","sequence":"additional","affiliation":[{"name":"Department of Oncology Yokohama City University Graduate School of Medicine Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Oncology Yokohama City University Graduate School of Medicine Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiko","family":"Tokuhisa","sequence":"additional","affiliation":[{"name":"Department of Oncology Yokohama City University Graduate School of Medicine Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"Department of Oncology Yokohama City University Graduate School of Medicine Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-011-0739-1"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-09-0078"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.191015"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8510"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316158"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000201398"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)78355-0"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011160913619"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.2553"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"issue":"2","key":"e_1_2_7_12_1","first-page":"S219","article-title":"Scintigraphy and radionuclide therapy with [indium\u2010111\u2013labelled \u2013diethyl triamine penta\u2010acetic acid\u2010D\u2010Phe1]\u2010octreotide","volume":"31","author":"Krenning EP","year":"1993","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800954"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.7873"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.2151"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_7_17_1","unstructured":"National Cancer Institute\u2010common toxicity criteria adverse events Versions 3 and 4.http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010\u201006"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-1902-1"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3041-6"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000348394"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-016-3527-x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2743"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.5865"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000443167"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000475526"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04709-x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-15-0543"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-014-0934-2"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0589"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0947"}],"container-title":["Journal of Hepato-Biliary-Pancreatic Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jhbp.1014","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jhbp.1014","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jhbp.1014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:21:30Z","timestamp":1692836490000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jhbp.1014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1002\/jhbp.1014"],"URL":"https:\/\/doi.org\/10.1002\/jhbp.1014","archive":["Portico"],"relation":{},"ISSN":["1868-6974","1868-6982"],"issn-type":[{"value":"1868-6974","type":"print"},{"value":"1868-6982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,14]]},"assertion":[{"value":"2021-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}